Piramal Pharma Limited has announced the completion of tenure of its Independent Director Mr. Subramanian Ramadorai, in compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The disclosure was made to both BSE Limited and National Stock Exchange of India Limited on February 5, 2026.

Director Tenure Details

Mr. Subramanian Ramadorai, holding Director Identification Number (DIN) 00000002, will complete his term of 5 consecutive years as Independent Director on February 8, 2026. The company has informed that Mr. Ramadorai expressed his desire to retire from the Board in the interest of pursuing personal priorities.

Board Transition and Committee Restructuring

Effective February 9, 2026, Mr. Ramadorai will cease to be an Independent Director of the company and consequently step down as Chairman/Member of various Board Committees on which he served. The Board has undertaken re-constitution of the Committees in accordance with applicable regulatory requirements to ensure continued compliance.

Board's Acknowledgment

The Board of Directors has placed on record its heartfelt gratitude for the valuable insights and guidance received from Mr. Ramadorai during his tenure. The company has specifically clarified that there is no material reason for his cessation other than his personal decision to retire and pursue personal priorities.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the SEBI Listing Regulations, demonstrating the company's commitment to maintaining transparency with stakeholders. The announcement was signed by Company Secretary Tanya Sanish and communicated to both stock exchanges where the company's shares are listed.

Piramal Pharma has announced the availability of its earnings call transcript for the quarter and nine months ended December 31, 2025, following the conference call held on January 29, 2026. The pharmaceutical company has made the transcript publicly accessible as part of its regulatory compliance obligations.

Regulatory Compliance Filing

The company filed the announcement with stock exchanges on January 30, 2026, in continuation of its earlier communication dated January 16, 2026. The filing was made pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Document Availability

The transcript of the conference call discussing the unaudited financial results (standalone and consolidated) has been made available on the company's official website at piramalpharma.com under the financial reports section. This follows the company's commitment to transparency and regulatory compliance in investor communications.

Exchange Communication

The announcement was formally communicated to both BSE Limited (scrip code: 543635) and National Stock Exchange of India Limited (symbol: PPLPHARMA). The filing was digitally signed by Company Secretary Tanya Sanish on January 30, 2026.

The availability of the earnings call transcript provides stakeholders with detailed insights into the company's Q3FY26 performance discussions and management commentary on the financial results for the reporting period.